Farma Mondo Group and Acadia Pharmaceuticals Inc. have entered into an Exclusive Distribution Agreement to globally manage Named Patient Supply of DAYBUE® (trofinetide) in specific countries, primarily in Asia-Pacific (ex-Japan), South Asia, Latin America, the Middle East and North Africa, South Africa, Russia and the Commonwealth of Independent States.
May 20th, 2025
CHIASSO, Switzerland and San Diego, US –May 20th, 2025 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, and Acadia Pharmaceuticals Inc. a biopharmaceutical company dedicated to developing and commercializing therapies that address unmet medical needs in central nervous system (CNS) disorders and rare diseases, have entered into an Exclusive Distribution Agreement to globally manage Named Patient Supply of DAYBUE® (trofinetide) in specific countries, primarily in Asia-Pacific (APAC-ex-Japan), South Asia, Latin Amecia (LATAM), the Middle East and North Africa (MENA), South Africa, Russia and the Commonwealth of Independent States (CIS). DAYBUE is the first and only FDA-approved treatment for Rett syndrome in adults and children 2 years of age and older.
All requests will be managed through the dedicated email trofinetide@farmamondo.com.
Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented: We are honored to partner with Acadia Pharmaceuticals to help make DAYBUE available to patients and families around the world who are living with Rett Syndrome. I want to thank the Acadia Team for their trust and collaboration in this important initiative. This agreement significantly expands access to this first and only approved therapy in an area where there is significant unmet need. We look forward to leveraging our infrastructure on behalf to bring Acadia’s innovation to patients. Together, we win.
About FarmaMondo Group
FarmaMondo is a fast-growing, Swiss-based group serving as a commercial partner of biotechnology companies in emerging markets.
The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets. Utilizing a phased approach tailored to emerging markets, we optimize regulatory and reimbursement pathways to unlock the full potential of products in line with our biopharma partner’s strategy.
About Acadia
Acadia is advancing breakthroughs in neuroscience to elevate life. The company has been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in the United States and Canada for the treatment of Rett syndrome. Acadia’s clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuroscience and neuro-rare diseases.
For more details, please visit https://www.acadia.com
